WeVote
Log In

Bill

Bill

HF 4373

Changes to provisions covering prescription drug prior authorizations, transactions with group purchasers, prescription drug price transparency, health maintenance organizations, network design, coverage for immunizations, access to certain data collected, and obsolete language made.

2025-2026 Regular Session Introduced by John Huot

Modernizes prescription drug prior authorization, expands price transparency, updates group-purchaser transactions, and tightens HMO/network rules to improve access and clarity.

Introduction and first reading, referred to Commerce Finance and Policy
#drugsandmedicine #healthandhealthdepartment #insurance-health
0
WeVote Research Nonpartisan
Bill Summary · HF 4373

Summary of HF 4373 (2025-2026) — Minnesota

Overview

HF 4373 is a Minnesota bill that proposes changes to multiple areas within health policy and insurance regulation. The measures appear to touch prescription drug processes, pricing transparency, contracting with group purchasers, health maintenance organizations (HMOs), network design, immunization coverage, data access, and obsolete language cleanup. The bill has one named sponsor (Co-sponsor: John Huot) and was introduced and referred to the Commerce Finance and Policy committee on March 16, 2026.

Primary Purpose

  • Modernize and streamline processes related to prescription drug prior authorizations (PAs).
  • Improve price transparency and reporting for prescription drugs.
  • Update rules governing transactions with group purchasers (likely involving negotiated pricing and contracts for groups such as employers or unions).
  • Adjust provisions related to health maintenance organizations (HMOs), network design, and coverage policies.
  • Expand or clarify access to data collected in health policy contexts.
  • Remove outdated or obsolete language to improve regulatory clarity.

Key Provisions and Changes

1) Prescription Drug Prior Authorizations

  • Reforms to how prior authorizations for prescription medications are initiated, reviewed, and approved.
  • Potential changes may include timelines for determinations, criteria standardization, or streamline processes to reduce delays for patients.

2) Transactions with Group Purchasers

  • Updates to rules governing transactions between payers/insurers and group purchasers.
  • May involve standardized contract terms, pricing practices, or compliance requirements to ensure fair and transparent dealings.

3) Prescription Drug Price Transparency

  • Provisions mandating or expanding reporting of drug prices, rebates, or other payer-facing cost information.
  • Aims to increase visibility into drug pricing for consumers, policymakers, and regulators.
  • Could include specific reporting timelines, metrics, or publication requirements.

4) Health Maintenance Organizations (HMOs) and Network Design

  • Revisions to HMO regulations, potentially affecting:
    • How networks are designed (which providers are included, access standards).
    • Minimum network adequacy requirements (e.g., time/distance standards, provider-to-member ratios).
    • Coverage terms within HMO plans, including benefits and exclusions.

5) Coverage for Immunizations

  • Changes to requirements around immunization coverage.
  • Could specify mandated coverage for vaccines, administration, and related services, or adjust cost-sharing rules (copayments, deductibles) for preventive immunizations.

6) Access to Data Collected

  • Measures to broaden or clarify who may access certain health data collected by regulators, plans, or other entities.
  • May include patient data access rights, research uses, or regulatory access for oversight and transparency.

7) Obsolete Language Cleanup

  • Repeal or modernization of outdated statutory language to reduce ambiguity and administrative burden.

Beneficiaries and Impact

  • Patients and Consumers: Potentially faster and more predictable access to prescription drugs due to streamlined PAs; improved price transparency may help compare costs and inform decisions; broader immunization coverage could reduce out-of-pocket costs and improve vaccination access.
  • Payers and Insurers: New or clarified requirements for PAs, group-purchaser transactions, and network design may affect administrative processes, contracting practices, and compliance obligations.
  • HMOs and Providers: Adjusted network design standards and HMO-related provisions may influence plan offerings, provider participation, and network adequacy.
  • Regulators and Data Holders: Expanded data access provisions could affect reporting, oversight capabilities, and research opportunities.

Procedural and Timeline Notes

  • Introduced and assigned to the Commerce Finance and Policy committee on March 16, 2026.
  • As of the current action history, the bill has completed its first reading and referral; further committee hearings and potential amendments would follow in subsequent sessions or committee meetings.

Additional Considerations

  • Specific dollar amounts, percentages, or exact timelines are not provided in the available action history. Readers should review the full bill text for precise provisions, definitions, and effective dates if enacted.
  • If you are advising stakeholders, monitor committee discussions for changes to PA standards, pricing transparency metrics, and network adequacy requirements, as these areas often generate significant impact on costs and access.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.